Treatment of chronic hepatitis B in adults with compensated liver disease with evidence of active viral replication, persistently elevated liver enzyme values, and histologically active disease, including those resistant to lamivudine.
Adults and adolescents ≥ 16 years of age:
Patients with chronic hepatitis B virus infection in nucleoside-treatment-naive: 0.5 mg once daily.
Patients with a history of hepatitis B viremia while receiving lamivudine or known lamivudine resistance mutations: 1 mg once daily.
Patients with renal impairment:
- ClCr ≥ 50mL/min: 0.5 mg once daily (Lamivudine-refractory: 1 mg once daily)
- ClCr 30 – < 50mL/ min: 0.25 mg once daily (Lamivudine-refractory: 0.5 mg once daily)
- ClCr 10 – < 30mL/ min: 0.15 mg once daily (Lamivudine-refractory: 0.3 mg once daily)
- ClCr < 10mL/ min (Hemodialysis (administer after hemodialysis) or continuous ambulatory peritoneal dialysis (CAPD)): 0.05 mg once daily (lamivudine-refractory: 0.1 mg once daily).
Entecavir STELLA 0.5 mg should be administered on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).